RLAY
Relay Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$19.18-3.67%
Price as of Jul 20, 2026
RLAY profitability
Relay Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -1121.9%
- EBITDA margin
- -2560.7%
- EBIT margin
- -2776.6%
- Net margin
- -2554.1%
- Free cash flow margin
- -1998.5%
Returns
- Return on equity
- -42.5%
- Return on assets
- -39.0%
- Return on invested capital
- -44.0%
- Asset turnover
- 0.02x
Cash efficiency
- Cash from operations
- -$213.4M
- Cash per share
- $3.35
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.